Acrivon Therapeutics posts Q3 loss, cash runway to Q4 2027 and GAAP EPS beat

Acrivon Therapeutics reported a net loss of $17.9 million for Q3 2026, slightly better than the $18.2 million loss a year earlier. The company held $77.8 million in cash and investments, which it expects to fund operations into Q4 2027. GAAP earnings per share were –$0.42, beating consensus by $0.02. The stock slipped 2.05% in after‑hours trading.

The cash balance gives the firm liquidity through the next fiscal year, reducing short‑term financing risk. The EPS beat shows marginally better profitability than analysts expected, though the share price fell, indicating market concern despite the beat.

Sources